- UroToday Home
- Recent Abstracts
- Urologic Oncology
Renal Cancer
The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
February 21, 2022
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?
February 21, 2022
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
February 21, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.
February 18, 2022
Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.
February 18, 2022
Renal Cell Carcinoma Surgical Treatment Disparities in American Indian/Alaska Natives and Hispanic Americans in Arizona.
February 17, 2022
The Next Paradigm Shift in the Management of Clear Cell Renal Cancer: Radiogenomics-Definition, Current Advances, and Future Directions.
February 17, 2022
Perspectives on the Role of Biopsy for Management of T1 Renal Masses: Survey Results from Two Regional Quality Improvement Collaboratives.
February 15, 2022
Partial vs. radical nephrectomy in non-metastatic pT3a kidney cancer patients: a population-based study.
February 15, 2022
Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
February 14, 2022
C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery.
February 14, 2022
Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
February 11, 2022
Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis.
February 11, 2022
PAQR5 Expression Is Suppressed by TGFβ1 and Associated With a Poor Survival Outcome in Renal Clear Cell Carcinoma.
February 10, 2022